|Bid||593.80 x 1000|
|Ask||596.99 x 800|
|Day's Range||586.17 - 597.00|
|52 Week Range||538.01 - 747.42|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||8.39|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||689.18|
Subscribe to Yahoo Finance Plus to view Fair Value for REGN
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
Regeneron (REGN) closed at $591.13 in the latest trading session, marking a -1.09% move from the prior day.
FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.